Developing a platform to analyze RNA modifications
Official title: Engineered RNA Modification Recognition
Funded at Alida Biosciences, INC. · NIH-10920516 · Data updated 2026-11-12
This study is working on a new tool that helps doctors and researchers better understand how tiny changes in RNA can affect health, especially in cancer, making it easier to use this information for diagnosis and treatment.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Alida Biosciences, INC. NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project start | May 1, 2023 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,082,339 |
| NIH project number | 9R44GM159290-02 |
| Project ID | NIH-10920516 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with cancers or conditions where RNA modifications play a significant role in disease progression or treatment response.
✕Less likely to help
Patients with conditions unrelated to RNA biology or those who do not have access to the necessary diagnostic tools may not benefit from this research.
What this research studies
This research focuses on creating a commercial platform that analyzes the epitranscriptome, which includes all the natural chemical modifications to RNA that regulate its various biological functions. By integrating engineered RNA modification binding agents, the platform aims to enhance the sensitivity and selectivity of RNA analysis, particularly for clinical samples. The technology will provide a user-friendly workflow and cloud-based data handling, making it easier for researchers and clinicians to utilize RNA modifications as diagnostic tools and therapeutic targets, especially in cancer treatment.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnostic and therapeutic strategies for cancer and other diseases by leveraging RNA modifications.
How similar studies have gone: Other research in the field of epitranscriptomics has shown promise, indicating that this approach could lead to significant advancements in understanding and treating diseases.
Where this research is happening
-
Alida Biosciences, INC.
San Diego, United States Active
Researchers
- Principal investigator: Miles, Zachary — Alida Biosciences, INC.
- Study coordinator: Miles, Zachary
Related research
Other NIH-funded projects on the same topics.
-
Pseudouridine detection with a multiplexed epitranscriptomics test
A new multiplexed test to detect key RNA chemical markings in human samples, helping researchers study how these marks influence health and disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.